About US
Contact us
-
Turbo test for chemical catalystsTurbo test for chemical catalysts 2010-09-21 P-10-413 Prof. Ferdi Schüth (MPI für Kohlenforschung, Mülheim), Dr. Dirk Demuth and Dr. Wolfram Stichert (hte AG, Heidelberg) have been nominated fo2010/9/26
-
Consumers need to be made aware of benefits of low-calorie sweetenersLeading experts in the field of food additive safety and risk communication gathered at a symposium hosted today by the Nutrition Research Foundation at the 2nd World Congress of Public Health Nutriti2010/9/26
-
Perrigo files NDA with FDA for generic Zegerid OTCPerrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for omeprazole 20mg/sodium bicarbonate 11002010/9/25
-
Porsolt Announces the Opening of a new Research Centre in the USA.Porsolt announces the continuation of its expansion strategy with the creation of a new preclinical Contract Research facility in San Antonio, Texas.Commencing operations in October 2010, the new faci2010/9/25
-
Genzyme announces Japanese approval of Synvisc viscosupplement for OA knee pain reliefGenzyme Corporation (Nasdaq: GENZ) announced today that Japan's Ministry of Health, Labour and Welfare has approved Synvisc® (hylan G-F 20; 3 x 2 mL), indicated for the treatment of osteoarthritis2010/9/21
-
Elias Shaker to sell Generex's novel consumer productsGenerex Biotechnology Corporation (Nasdaq: GNBT), (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into2010/9/21
-
Preparing for Mandatory Electronic Submission of Drug Establishment Registration and Drug Listing InformationPreparing for Mandatory Electronic Submission of Drug Establishment Registration and Drug Listing Information Prepared by Gina A. Ross and Greg A. Onyszchuk, Ph.D. Introduction United States2010/9/20
-
Johnson & Johnson in talks to buy CrucellJohnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst2010/9/20
-
CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine developmentCytoGenix, Inc. (Pink Sheets:CYGX) today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furtherin2010/9/19
-
PharmaZell Continues Expansion of Pharmaceutical Manufacturing Capacity in IndiaVizag, India (September 20, 2010) – PharmaZell GmbH, a European Contract Manufacturing Organization for active pharmaceutical ingredients and advanced intermediates, has once again expanded its manu2010/9/19